By Dr Nan Hu

Journal articles

Chau I; Ajani JA; Kitagawa Y; Xu J; Wyrwicz LS; Motoyama S; Ogata T; Kawakami H; Hsu C-H; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Blum Murphy MA; Nathani R; Hu N; Matsumura Y; Kato K; Doki Y, 2024, 'Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648.', Journal of Clinical Oncology, 42, pp. 4034 - 4034, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.4034

Lim SA; Chan M; Hu N; McMullan B; Britton PN; Bartlett A; Kandasamy R; Saravanos GL; Prentice B; Jaffe A; Owens L; Homaira N, 2024, 'Risk Factors and Clinical Prognosis Associated with RSV-ALRI Intensive Care Unit Admission in Children <2 Years of Age: A Multicenter Study', Pediatric Infectious Disease Journal, 43, pp. 511 - 517, http://dx.doi.org/10.1097/INF.0000000000004288

Hu N; Gelaw YA; Katz I; Fernandez E; Falster K; Hanly M; Newton BJ; Stephensen J; Hotton P; Zwi K; Lingam R, 2024, 'Developmental trajectories of socio-emotional outcomes of children and young people in out-of-home care – Insights from data of Pathways of Care Longitudinal Study (POCLS)', Child Abuse and Neglect, 149, http://dx.doi.org/10.1016/j.chiabu.2023.106196

Newton BJ; Katz I; Gray P; Frost S; Gelaw Y; Hu N; Lingam R; Stephensen J, 2024, 'Restoration from out-of-home care for Aboriginal children: Evidence from the pathways of care longitudinal study and experiences of parents and children', Child Abuse and Neglect, 149, http://dx.doi.org/10.1016/j.chiabu.2023.106058

Rashid MM; Ahmed S; Owens L; Hu N; Jaffe A; Homaira N, 2024, 'Asthma-community acquired pneumonia co-diagnosis in children: a scoping review', Journal of Asthma, 61, pp. 282 - 291, http://dx.doi.org/10.1080/02770903.2023.2280843

Tellegen CL; Schoch M; Hodges J; Peters K; Sanders MR; Tonge B; Einfeld S; Sofronoff K; Gray KM; Howlin P; Emerson E; Arciuli J; Rice L; Horstead S; Clarke K; Bezzina L; Evans H; Andersson E; McAuliffe Z; Haas K; Louie E; Hoath F; Worrall S; Stace L; Silove N; Kostelas P; Caruana J; Dossetor D; Salvador-Carulla L; Henderson K; Phillis K; Rotolone C; Henry T; Panahi B; Aery A; Hinton S; Thompson DM; Ommensen B; Mazzucchelli T; Taffe J; Hu N; Boland R; Knott R; O'Hagan G; Rose O; Shortt F; Cawood D; Blackmore R; Wallman E; Keating C; Teague S; Viney R; Goodall S; Arora S, 2024, 'The role of social identity and self-efficacy in predicting service providers’ use of Stepping Stones Triple P following training', Children and Youth Services Review, 156, http://dx.doi.org/10.1016/j.childyouth.2023.107318

Adenis A; Chau I; Ajani JA; Kitagawa Y; Xu J; Wyrwicz LS; Motoyama S; Ogata T; Kawakami H; Hsu C-H; Hajbi FE; Di Bartolomeo M; Braghiroli MI; Holtved E; Murphy MB; Zhang J; Hu N; Matsumura Y; Kato K; Doki Y, 2024, '398P Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Additional analysies from 45-month (mo) follow-up of CheckMate 648', Annals of Oncology, 35, pp. s161 - s162, http://dx.doi.org/10.1016/j.annonc.2024.05.313

Reck M; Ciuleanu T-E; Schenker M; Bordenave S; Cobo M; Juan-Vidal O; Reinmuth N; Richardet E; Felip E; Menezes J; Cheng Y; Mizutani H; Zurawski B; Alexandru A; Carbone DP; Lu S; John T; Aoyama T; Grootendorst DJ; Hu N; Eccles LJ; Paz-Ares LG, 2024, 'Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial', European Journal of Cancer, 211, pp. 114296, http://dx.doi.org/10.1016/j.ejca.2024.114296

Barlesi F; Yao W; Duruisseaux M; Doucet L; Shi J; Vidal OJJ; Kim Y-C; Campelo MRG; Martínez AA; Lu S; Jotte R; Felip E; Russo GL; Reck M; Zhang Y; Hu N; Michenzie MF; Mok TSK, 2024, 'LBA57 Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): Results from KRYSTAL-12', Annals of Oncology, 35, pp. s1247 - s1248, http://dx.doi.org/10.1016/j.annonc.2024.08.2299

Kato K; Doki Y; Chau I; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu C; Adenis A; Hajbi FE; Di Bartolomeo M; Braghiroli MI; Holtved E; Makino T; Murphy MB; Amaya‐Chanaga C; Patel A; Hu N; Matsumura Y; Kitagawa Y; Ajani J, 2024, 'Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial', Cancer Medicine, 13, pp. e7235, http://dx.doi.org/10.1002/cam4.7235

Badin F; Carbone DP; Ciuleanu T-E; Schenker M; Cobo-Dols M; Bordenave S; Juan-Vidal O; Menezes J; Reinmuth N; Richardet E; Cheng Y; Mizutani H; Paz-Ares LG; Lu S; John T; Zhang X; Hu N; Balli D; Baxi V; Neely J; Reck M, 2024, 'PP01.118 First-line Nivolumab (N) + Ipilimumab (I) + Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update', Journal of Thoracic Oncology, 19, pp. e51, http://dx.doi.org/10.1016/j.jtho.2024.05.343

Hodgins M; McHugh C; Eapen V; Hu N; Cadiri M; Curtis J; Lingam R, 2023, 'A framework for evaluating the implementation and maintenance of integration within the youth mental health system.', International Journal of Integrated Care, 23, pp. 518, http://dx.doi.org/10.5334/ijic.icic23537

Wolfe I; Forman J; Cecil E; Newham J; Hu N; Satherley R; Soley-Bori M; Fox-Rushby J; Cousens S; Lingam R, 2023, 'Effect of the Children and Young People's Health Partnership model of paediatric integrated care on health service use and child health outcomes: a pragmatic two-arm cluster randomised controlled trial', Lancet Child and Adolescent Health, 7, pp. 830 - 843, http://dx.doi.org/10.1016/S2352-4642(23)00216-X

Amarasena L; Zwi K; Hu N; Lingam R; Raman S, 2023, 'Changing landscape of paediatric refugee health in South Western Sydney, Australia: A retrospective observational study', BMJ Open, 13, http://dx.doi.org/10.1136/bmjopen-2022-064497

Lingam R; Smithers-Sheedy H; Hodgson S; Hutchinson K; Morris TM; Hu N; Nassar N; Schroeder EA; Rana R; Dickins E; Bula K; Zurynski Y, 2023, 'Evaluation of RuralkidsGPS; A Novel Integrated Paediatric Care Coordination Model of Care in Rural Australia – a Mixed-Methods Study Protocol', International Journal of Integrated Care, 23, http://dx.doi.org/10.5334/ijic.7008

Fardell JE; Hu N; Wakefield CE; Marshall G; Bell J; Lingam R; Nassar N, 2023, 'Impact of Hospitalizations due to Chronic Health Conditions on Early Child Development', Journal of Pediatric Psychology, 48, pp. 799 - 811, http://dx.doi.org/10.1093/jpepsy/jsad025

John JR; Khan JR; Lin PI; Jonnagaddala J; Hu N; Belcher J; Liaw ST; Lingam R; Eapen V, 2023, 'A nationwide study of COVID-19 impact on mental health-related presentations among children and adolescents to primary care practices in Australia', Psychiatry Research, 326, http://dx.doi.org/10.1016/j.psychres.2023.115332

David-Wilathgamuwa S; Hu N; Meyers T; O'Loughlin R; Lingam R, 2023, 'Socioemotional and behavioural difficulties in children with chronic physical conditions: Analysis of the Longitudinal Study of Australian Children', Archives of Disease in Childhood, 108, pp. 569 - 575, http://dx.doi.org/10.1136/archdischild-2022-325069

Carbone DP; Ciuleanu T-E; Schenker M; Cobo-Dols M; Bordenave S; Juan-Vidal O; Janoski De Menezes J; Reinmuth N; Richardet E; Cheng Y; Mizutani H; Paz-Ares LG; Lu S; John T; Zhang X; Hu N; Balli D; Baxi V; Neely J; Reck M, 2023, 'First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).', Journal of Clinical Oncology, 41, pp. lba9023 - lba9023, http://dx.doi.org/10.1200/jco.2023.41.17_suppl.lba9023

Spicer J; Forde PM; Provencio M; Lu S; Wang C; Mitsudomi T; Broderick S; Swanson S; Awad MM; Felip E; Brahmer JR; Kerr K; Saylors GB; Chen K-N; Tanaka F; Cai J; Mahmood J; Hu N; Tran P; Girard N, 2023, 'Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.', Journal of Clinical Oncology, 41, pp. 8521 - 8521, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.8521

Southcombe F; Vivekanandarajah S; Krstic S; Lin F; Chay P; Williams M; Khan JR; Hu N; Eapen V; Dennis S; Denney-Wilson E; Lingam R, 2023, 'More than just body mass index: Using the Edmonton obesity staging system for pediatrics to define obesity severity in a multi-ethnic Australian pediatric clinical cohort', Obesity Science and Practice, 9, pp. 285 - 295, http://dx.doi.org/10.1002/osp4.648

Khan JR; Hu N; Lin PI; Eapen V; Nassar N; John J; Curtis J; Rimmer M; O’Leary F; Vernon B; Lingam R, 2023, 'COVID-19 and Pediatric Mental Health Hospitalizations', Pediatrics, 151, http://dx.doi.org/10.1542/peds.2022-058948

Khan JR; Muurlink O; Hu N; Awan N; Lingam R, 2023, 'Pregnancy, spousal connectedness, and young married women’s mental health: an analysis of the Bangladesh adolescent health and wellbeing survey', Archives of Women S Mental Health, 26, pp. 235 - 244, http://dx.doi.org/10.1007/s00737-023-01302-7

Amarasena L; Samir N; Sealy L; Hu N; Rostami MR; Isaacs D; Gunasekera H; Young H; Agrawal R; Levitt D; Francis JR; Coleman J; Mares S; Larcombe P; Cherian S; Raman S; Lingam R; Zwi K, 2023, 'Offshore detention: cross-sectional analysis of the health of children and young people seeking asylum in Australia', Archives of Disease in Childhood, 108, pp. 185 - 191, http://dx.doi.org/10.1136/archdischild-2022-324442

Kato K; Ajani JA; Doki Y; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu C-H; Adenis A; Hajbi FE; Di Bartolomeo M; Braghiroli MIFM; Holtved E; Murphy MAB; Patel A; Hu N; Matsumura Y; Chau I; Kitagawa Y, 2023, 'Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.', Journal of Clinical Oncology, 41, pp. 290 - 290, http://dx.doi.org/10.1200/jco.2023.41.4_suppl.290

Li D; Yu YY; Hu N; Zhang M; Sun FL; Liu L; Fan LM; Ruan SS; Wang F; Rosa-Neto P; Yu JT, 2023, 'Composite Indices of the Color-Picture Version of Boston Naming Test Have Better Discriminatory Power: Reliability and Validity in a Chinese Sample with Diverse Neurodegenerative Diseases', Journal of Alzheimer S Disease, 94, pp. 393 - 404, http://dx.doi.org/10.3233/JAD-221227

Awad MM; Forde PM; Girard N; Spicer JD; Wang C; Lu S; Mitsudomi T; Felip E; Broderick S; Swanson SJ; Brahmer JR; Kerr KM; Saylors G; Chen K-N; Cai JL; Mahmood J; Neely J; Balli D; Hu N; Pulla MP, 2023, '1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial', Annals of Oncology, 34, pp. s731, http://dx.doi.org/10.1016/j.annonc.2023.09.739

Spicer J; Wang C; Tanaka F; Chen K-N; Ito H; Liberman M; Chen Q; Girard N; Lu S; Provencio M; Mitsudomi T; Awad M; Felip E; Swanson S; Forde P; Cai J; Mahmood J; Hu N; Tran P; Broderick S, 2023, '60 Event-free survival (EFS) with neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo by surgical outcomes in resectable non-small cell lung cancer (NSCLC) from CheckMate 816', Lung Cancer, 178, pp. s26 - s27, http://dx.doi.org/10.1016/s0169-5002(23)00487-7

Forde PM; Spicer J; Girard N; Provencio M; Lu S; Wang C; Awad M; Mitsudomi T; Felip E; Swanson SJ; Saylors G; Chen K-N; Tanaka F; Tran P; Hu N; Cai J; Bushong J; Neely J; Balli D; Broderick SR, 2023, '84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816', Journal of Thoracic Oncology, 18, pp. s89 - s90, http://dx.doi.org/10.1016/s1556-0864(23)00338-6

Zalcman G; Oulkhouir Y; Cornelissen R; Greillier L; Cid JR; Mazières J; Briggs P; Nowak AK; Tsao AS; Fujimoto N; Peters S; Mansfield AS; Popat S; Nassar A; Bushong J; Hu N; Spires TE; Balli D; Eccles L; Baas P, 2023, 'Nivolumab (NIVO) plus ipilimumab (IPI) vs chimiothérapie (chimio) en traitement de première ligne du mésothéliome pleural malin (MPM) non résécable : résultats à 4 ans de l’étude CheckMate 743', Revue des Maladies Respiratoires Actualités, 15, pp. 138 - 139, http://dx.doi.org/10.1016/j.rmra.2022.11.197

Carbone DP; Paz-Ares LG; Ciuleanu TE; Cobo-Dols M; Bennouna J; Cheng Y; Mizutani H; Lingua A; Reyes F; Reinmuth N; Menezes J; Jassem J; Protsenko S; Feeney K; de la Mora Jimenez E; Lu S; John T; Zhang X; Hu N; Reck M, 2023, 'OA01.04 First-Line Nivolumab + Ipilimumab + Chemotherapy in Metastatic NSCLC: CheckMate 9LA 3-Year Update', Journal of Thoracic Oncology, 18, pp. e2, http://dx.doi.org/10.1016/j.jtho.2022.09.121

Homaira N; Hu N; Owens L; Chan M; Gray M; Britton PN; Selvadurai H; Lingam R; Jaffe A, 2022, 'Impact of lockdowns on paediatric asthma hospital presentations over three waves of COVID-19 pandemic', Allergy Asthma and Clinical Immunology, 18, http://dx.doi.org/10.1186/s13223-022-00691-1

Hodgins M; Ostojic K; Hu N; Lawson KD; Samir N; Webster A; Rogers H; Henry A; Murphy E; Lingam R; Raman S; Mendoza Diaz A; Dadich A; Eapen V; Rimes T; Woolfenden S, 2022, 'Study protocol for a real-world evaluation of an integrated child and family health hub for migrant and refugee women', BMJ Open, 12, pp. e061002, http://dx.doi.org/10.1136/bmjopen-2022-061002

Paz-Ares LG; Ciuleanu T-E; Cobo-Dols M; Bennouna J; Cheng Y; Mizutani H; Lingua A; Reyes F; Reinmuth N; De Menezes JJ; Jassem J; Protsenko S; Feeney K; De La Mora Jimenez E; Lu S; John T; Carbone DP; Zhang X; Hu N; Reck M, 2022, 'First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.', Journal of Clinical Oncology, 40, pp. lba9026 - lba9026, http://dx.doi.org/10.1200/jco.2022.40.17_suppl.lba9026

Li D; Yu YY; Hu N; Zhang M; Liu L; Fan LM; Ruan SS; Wang F, 2022, 'A Color-Picture Version of Boston Naming Test Outperformed the Black-and-White Version in Discriminating Amnestic Mild Cognitive Impairment and Mild Alzheimer's Disease', Frontiers in Neurology, 13, http://dx.doi.org/10.3389/fneur.2022.884460

Mimmo L; Harrison R; Travaglia J; Hu N; Woolfenden S, 2022, 'Inequities in quality and safety outcomes for hospitalized children with intellectual disability', Developmental Medicine and Child Neurology, 64, pp. 314 - 322, http://dx.doi.org/10.1111/dmcn.15066

Hu N; Fardell J; Wakefield CE; Marshall GM; Bell JC; Nassar N; Lingam R, 2022, 'School academic performance of children hospitalised with a chronic condition', Archives of Disease in Childhood, 107, pp. 289 - 296, http://dx.doi.org/10.1136/archdischild-2020-321285

Saravanos GL; Hu N; Homaira N; Muscatello DJ; Jaffe A; Bartlett AW; Wood NJ; Rawlinson W; Kesson A; Lingam R; Britton PN, 2022, 'RSV Epidemiology in Australia Before and During COVID-19', Pediatrics, 149, http://dx.doi.org/10.1542/peds.2021-053537

Hu N; Nassar N; Shrapnel J; Perkes I; Hodgins M; O'Leary F; Trudgett C; Eapen V; Woolfenden S; Knight K; Lingam R, 2022, 'The impact of the COVID-19 pandemic on paediatric health service use within one year after the first pandemic outbreak in New South Wales Australia – a time series analysis', Lancet Regional Health Western Pacific, 19, http://dx.doi.org/10.1016/j.lanwpc.2021.100311

Homaira N; Binks M; Walker G; Larter N; Clark K; Campbell M; McHugh L; Briggs N; Nyiro J; Stelzer-Braid S; Hu N; Macartney K; Snelling T; Omer SB; Rawlinson W; Andrews R; Jaffe A, 2022, 'Transplacental transfer of RSV antibody in Australian First Nations infants', Journal of Medical Virology, 94, pp. 782 - 786, http://dx.doi.org/10.1002/jmv.27383

John T; Ciuleanu T-E; Dols MC; Schenker M; Zurawski B; Menezes J; Richardet EA; Bennouna J; Cheng Y; Felip E; Vidal OJJ; Alexandru A; Paz-Ares L; Lu S; Reck M; Hu N; Zhang X; Grootendorst DJ; Eccles L; Carbone DP, 2022, '1049P Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA', Annals of Oncology, 33, pp. s1034, http://dx.doi.org/10.1016/j.annonc.2022.07.1175

Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Spires T; Zalcman G, 2022, 'First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743', Annals of Oncology, 33, pp. 488 - 499, http://dx.doi.org/10.1016/j.annonc.2022.01.074

Zalcman G; Oulkhouir Y; Cornelissen R; Greillier L; Cid JRR; Mazieres J; Briggs P; Nowak AK; Tsao A; Fujimoto N; Peters S; Mansfield AS; Popat S; Nassar A; Bushong J; Hu N; Spires T; Balli D; Eccles L; Baas P, 2022, 'LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743', Annals of Oncology, 33, pp. s1438 - s1439, http://dx.doi.org/10.1016/j.annonc.2022.08.077

Harding G; Hu N; Larter N; Montgomery A; Stephensen J; Callaghan L; Zwi K; Lingam R; Woolfenden S, 2021, 'Health status and health service use of urban Aboriginal children attending an Aboriginal community child health service in Sydney', Journal of Paediatrics and Child Health, 57, pp. 1072 - 1077, http://dx.doi.org/10.1111/jpc.15403

Reck M; Ciuleanu TE; Pluzanski A; Lee JS; Bernabe R; Linardou H; Burgers J; Gallardo C; Nishio M; Peters S; Paz-Ares LG; Hellmann MD; Borghaei H; Ramalingam SS; O’Byrne K; Hu N; Bushong J; Eccles L; Grootendorst D; Brahmer JR, 2021, '122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1', Annals of Oncology, 32, pp. s1430 - s1431, http://dx.doi.org/10.1016/j.annonc.2021.10.141

Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Sanzari J; Zalcman G, 2021, 'LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743', Annals of Oncology, 32, pp. s1341 - s1342, http://dx.doi.org/10.1016/j.annonc.2021.08.2146

Carbone D; Ciuleanu T; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; De La Mora Jimenez E; Paz-Ares L; Reck M; John T; Hu N; Zhang X; Tran P; Grootendorst DJ; Lu S, 2021, 'OA09.01 First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA', Journal of Thoracic Oncology, 16, pp. s862, http://dx.doi.org/10.1016/j.jtho.2021.08.061

Borland RL; Hu N; Tonge B; Einfeld S; Gray KM, 2020, 'Participation in sport and physical activity in adults with intellectual disabilities', Journal of Intellectual Disability Research, 64, pp. 908 - 922, http://dx.doi.org/10.1111/jir.12782

Britton PN; Hu N; Saravanos G; Shrapnel J; Davis J; Snelling T; Dalby-Payne J; Kesson AM; Wood N; Macartney K; McCullagh C; Lingam R, 2020, 'COVID-19 public health measures and respiratory syncytial virus', Lancet Child and Adolescent Health, 4, pp. e42 - e43, http://dx.doi.org/10.1016/S2352-4642(20)30307-2

Bell J; Lingam R; Wakefield CE; Fardell JE; Zeltzer J; Hu N; Woolfenden S; Callander E; Marshall GM; Nassar N, 2020, 'Prevalence, hospital admissions and costs of child chronic conditions: A population-based study', Journal of Paediatrics and Child Health, 56, pp. 1365 - 1370, http://dx.doi.org/10.1111/jpc.14932

Back to profile page